← Back

Neuraxis, Inc.

NeurAxis, Inc. is a medical technology company focused on developing neuromodulation therapies for chronic and debilitating conditions in children and adults in the United States. Its product IB-Stim is a percutaneous electrical nerve field stimulation system intended for patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD), and associated FD nausea symptoms. The company also offers a rectal expulsion device, a screening tool that helps detect evacuation disorders. It sells its products to healthcare companies such as hospitals and clinics. Formerly known as Innovative Health Solutions, Inc., it changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.

Price · split & dividend adjusted
News & notes moving NRXS
NRXS▲

NeurAxis Wins National Insurer Coverage for PENFS, Adding 18 Million Covered Lives

NeurAxis announced new medical policy coverage from a major national health insurer for its Percutaneous Electrical Nerve Field Stimulation technology, a decision that adds approximately 18 million health plan members across multiple states. The company said the new policy lifts the total national coverage footprint for PENFS to more than 120 million covered lives. NeurAxis' proprietary PENFS technology, marketed as IB-Stim, is FDA-cleared for functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia, including associated nausea symptoms, in patients 8 years and older. Chief Executive Officer Brian Carrico said the coverage win demonstrates tangible progress on the company's payer expansion plans and that NeurAxis is actively pursuing additional major national insurers. Carrico also pointed to a Category I CPT code effective January 1, 2026, and the inclusion of PENFS in leading national society clinical practice guidelines as foundations for broader physician adoption and commercial expansion.
NRXS ▲
GlobeNewswire·2dRead more →
NRXS

Eastman Kodak Revenue Jumps 18% as Zacks Flags Watchlist Stock

Eastman Kodak Company is showing signs of an operational turnaround, with total revenues growing 18% year over year to $311 million in the latest quarter. Within that total, print revenue rose 10% year over year to $195 million, while the Advanced Materials and Chemicals segment grew revenue 40% year over year to $105 million. Gross margin expanded 700 basis points year over year to 26%, helping lift Operational EBITDA to $36 million from $9 million in the prior year, which on a pro-forma annual run-rate basis would be $144 million against an enterprise value of about $731 million. Zacks Investment Research said it remains Neutral on the stock, citing slightly negative free cash flow of about $1 million for the quarter and a need for consistent operational improvement. Zacks also flagged NeurAxis, Inc. as a watchlist stock, noting its revenue more than doubled to $1.9 million from $0.9 million a year earlier, its gross margin of 85.9%, a 28% year-over-year increase in selling price, and a widened operating loss of $2.1 million from $1.7 million, while keeping a Neutral rating on valuation, lack of operating leverage, and share dilution from its ATM.
KODK ▲NRXS
Zacks Investment Research·7dRead more →
© 2026 MarketDXAsset